rethinkTHC Search
Menu
Study breakdown

Brief incentivized abstinence changed cannabis attitudes and reduced use even after incentives stopped

Randomized Controlled TrialHigh evidence
The takeaway

After 4 weeks of incentivized cannabis abstinence, 68% of non-treatment-seeking youth wanted to reduce or quit, and those without cannabis use disorder showed significant reductions in use even 4 weeks after incentives ended.

People interested in harm reduction approaches for cannabis use among young people not seeking treatment.

68.4% wanted to reduce or quit after experiencing abstinence

What the researchers found

Abstinence-incentivized participants showed significant reductions in cannabis use frequency and biochemically verified THC metabolites at 4-week follow-up compared to monitoring-only controls. 68.4% of abstinence participants set goals to reduce or quit after the intervention. Those without CUD who set reduction goals showed the greatest decreases.

Why it matters

Most young cannabis users are not seeking treatment. This study shows that a brief period of incentivized abstinence can shift attitudes and reduce use even in youth who were not motivated to change, suggesting a viable harm reduction strategy.

The numbers in context

220 participants. Group-by-time interaction significant (days/week: p=.005; times/week: p<.001; CN-THCCOOH: p=.004). 68.4% set reduction/abstinence goals post-intervention. Greatest reductions in those without CUD who set goals.

How the study worked

Randomized trial of 220 non-treatment-seeking youth. 126 randomized to 4-week abstinence-based contingency management (incentivized) and 94 to monitoring only. Cannabis use measured by self-report and creatinine-adjusted urine THC-COOH at baseline, end of intervention, and 4-week follow-up.

What this study cannot tell us

Relatively short follow-up (4 weeks post-intervention). Youth without CUD responded best, so this may be less effective for those with established disorders. Financial incentives may not be scalable in all settings. Cannot determine durability beyond 4 weeks.

How to read the evidence

Randomized controlled trial with biochemical verification of cannabis use. Strong design, though limited by short follow-up and the finding that CUD patients responded less well.

When this study was published

Published in 2024 in Drug and Alcohol Dependence.

The bigger picture

Contingency management is well-established for other substances but underused for cannabis. This study demonstrates it can generate motivation to change even in people who were not looking for help, which could be valuable as cannabis use becomes more normalized.

Questions still open

  • How long do the attitude and behavior changes persist beyond 4 weeks? Would booster incentive periods maintain the gains? Could this approach be implemented in school or primary care settings?

Common questions

Can incentives help people cut back on cannabis?
Yes. After just 4 weeks of incentivized abstinence, 68% of non-treatment-seeking youth decided they wanted to use less or quit. Those without a cannabis use disorder showed the strongest lasting reductions in use.
Did the benefits last after incentives stopped?
At 4-week follow-up after incentives ended, the abstinence group still showed significant reductions in cannabis use frequency and THC metabolite levels compared to the monitoring group, suggesting the experience of abstinence itself created lasting change.

Read the original research

Contingency management is associated with positive changes in attitudes and reductions in cannabis use even after discontinuation of incentives among non-treatment seeking youth.

Drug and alcohol dependence, 256, 111096

Citation

Cooke, Megan E; Knoll, Sarah J; Streck, Joanna M; Potter, Kevin; Lamberth, Erin; Rychik, Natali; Gilman, Jodi M; Evins, A Eden; Schuster, Randi M. (2024). Contingency management is associated with positive changes in attitudes and reductions in cannabis use even after discontinuation of incentives among non-treatment seeking youth.. Drug and alcohol dependence, 256, 111096. https://doi.org/10.1016/j.drugalcdep.2024.111096

Explore the wider topic